10 / 10
Volume 7, Issue 6 (Suppl)
Clin Exp Pharmacol, an open access journal
ISSN: 2161-1459
Page 41
Notes:
December 14-16, 2017 Rome, Italy
International Conference on
2
nd
International Conference on
&
Toxicology and Clinical Pharmacology
Generic Drugs and Biosimilars
CO-ORGANIZED EVENT
Impact of value-based pricing on market access in mature, emerging, and developing economies
O
utcomes-based agreements, which ensure that drug companies are paid for actual not potential benefits to patients are
another way to better align pricing and coverage of drugs with their value, resulting in so-called value-based pricing
(VBP). One in four health plans now have at least one outcomes-based contract with a drug maker, an Avalere Health survey
showed. In this presentation, we will examine various factors that impact prospects for implementing such arrangements in
mature, emerging, and developing markets such as: pre-existing price structures, legal prohibitions, capacity for measuring
outcomes, influence of prescriber resistance, who the payer is (i.e., self-pay vs. universal insurance coverage), etc. Another
consideration is that while more countries are using Health Technology Assessments (HTAs) in reimbursement decisions,
healthcare payers are increasingly demanding real-world evidence (RWE) of value. Yet another set of considerations are still
evolving in importance. For example, only 25 percent of drug company CEOs surveyed say that their company involves patients
or advocacy groups in the drug price-setting process, but another 27 percent say they don’t involve patients now, but plan to
do so in the future.
Biography
Christopher Milne has joined the Center for the Study of Drug Development at the Tufts University School of Medicine (Tufts CSDD) in 1998 as a Senior Research Fellow
and has published over 70 book chapters, white papers, and journal articles. Currently, his research interests include: academic-industry collaborations; disease, demo-
graphic and market access factors in the emerging markets; incentive programs for pediatric studies, orphan products, neglected diseases, breakthrough therapies, and
medical countermeasures (MCMs); and, tracking the progress of new regulatory and research initiatives such as regulatory science, translational medicine, personalized
medicine, and FDA User Fee programs.
Christopher.Milne@tufts.eduChristopher Milne
Tufts University, USA
Christopher Milne, Clin Exp Pharmacol 2017, 7:6(Suppl)
DOI: 10.4172/2161-1459-C1-024